Sofituzumab vedotin (solution)_product_DataBase

Bioactivity	Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker[1][2].
Invitro	Sofituzumab vedotin (3A5-VC-MMAE; 0.1-10000 ng/mL; 3 or 5 days) 以剂量依赖方式抑制 OVCAR-3 和 PC3/MUC16TMlong 细胞增殖[3]。 0 --> Sofituzumab vedotin (solution) 相关抗体: Cell Proliferation Assay[1] Cell Line:
In Vivo	Sofituzumab vedotin (3A5-VC-MMAE; 2 and 2.8 mg/kg; IV; once weekly for 3 or 4 total doses) 在 MUC16 表达的人 OVCAR-3 小鼠异种移植物模型中显示出强大的抗肿瘤活性[3]。 Animal Model:
Name	Sofituzumab vedotin (solution)
CAS	1418200-58-4
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Manzano A, et al. Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. Cancers (Basel). 2020 Aug 9;12(8):2223. [2]. Liu JF, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 Nov;27(11):2124-2130. [3]. Chen Y, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007 May 15;67(10):4924-32.

PeptideDB